Drugs / CN128
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03935633 | Dec 2018 → May 2019 | thalassemia | Hangzhou Zede Pharma-Tech Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03673085 | Jan → Oct 2018 | thalassemia | Hangzhou Zede Pharma-Tech Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05355766 | Jun 2022 → Sep 2024 | disorder of iron metabolism and transport, thalassemia | Hangzhou Zede Pharma-Tech Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04614779 | Sep 2020 → Aug 2022 | disorder of iron metabolism and transport, thalassemia | Hangzhou Zede Pharma-Tech Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CN128 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03673085 ↗ |
| Route | Oral | “single oral administration” NCT03673085 ↗ |